BIO-TECHNE Corp Available-for-sale Securities, Gross Realized Gain (Loss)
BIO-TECHNE Corp (TECH) reported Available-for-sale Securities, Gross Realized Gain (Loss) of $23.70 million for the 9-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet · last filed 2018-05-09
- 2018-03-31: Available-for-sale Securities, Gross Realized Gain (Loss) 9 month $23.70M.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss) 9 month |
|---|---|
| 2018-03-31 | $23.70M 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |